Bayer: a bitter pill to swallow

Bayer is being sued in the US over adverse side effects produced by anti-cholesterol drug Baycol. The firm also faces lower demand for its chemical and polymer products and needs to reduce leverage by selling assets. Is Bayer a deteriorating credit or are the firm’s woes little more than bad news stories?


Bayer has been shaken by widespread litigation concerning its ill-fated anti-cholesterol drug, Baycol. Despite winning its first major US court case, in Corpus Christi, Texas, a factor that softened market sentiment towards Bayer, future lawsuits are still a big thorn in the German company’s side. The victory does set a favourable precedent, but the decision should not be viewed as the end of Bayer’s troubles, as each individual case differs in its circumstances.

The German pharmaceuticals

Only users who have a paid subscription or are part of a corporate subscription are able to print or copy content.

To access these options, along with all other subscription benefits, please contact or view our subscription options here:

You are currently unable to copy this content. Please contact to find out more.

Sorry, our subscription options are not loading right now

Please try again later. Get in touch with our customer services team if this issue persists.

New to View our subscription options

Most read articles loading...

You need to sign in to use this feature. If you don’t have a account, please register for a trial.

Sign in
You are currently on corporate access.

To use this feature you will need an individual account. If you have one already please sign in.

Sign in.

Alternatively you can request an individual account here